Analytical Data
-
Gene name
IFNL3
- Application
-
Alternative Names
IFNL3；IL28B；IL28C；ZCYTO22；Interferon lambda-3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q8IZI9
-
Expression Region
22-196aa
-
AA Sequence
VPVARLRGA LPDARGCHIA QFKSLSPQEL QAFKRAKDAL EESLLLKDCK CRSRLFPRTW DLRQLQVRER PVALEAELAL TLKVLEATAD TDPALGDVLD QPLHTLHHIL SQLRACIQPQ PTAGPRTRGR LHHWLHRLQE APKKESPGCL EASVTFNLFR LLTRDLNCVA SGDLCV
-
Molecular Weight
21.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNL3, also known as interleukin-28A, is a significant member of the interferon lambda family, which plays a crucial role in the innate immune response, particularly against viral infections. Recent studies have highlighted its potential in modulating immune responses, making it a point of interest for therapeutic applications, especially in the context of chronic viral infections such as hepatitis C and certain cancers. Research has shown that IFNL3 can influence the efficacy of antiviral therapies and has been associated with different clinical outcomes based on genetic variations in its receptor. The recombinant protein of IFNL3, produced through genetic engineering techniques, allows for the detailed study of its biological functions and interactions at a molecular level. Understanding its signaling pathways and biological effects is essential for developing IFNL3-based therapies that could enhance antiviral responses or be used in combination with existing treatments. This research not only extends our grasp of the immune system's mechanisms but also opens avenues for innovative treatment strategies in viral pathologies and beyond. The growing body of evidence supporting IFNL3's role in immune regulation underlines its potential as a biomarker for disease prognosis and a target for novel therapeutics, making the study of IFNL3 recombinant protein a timely and relevant endeavor in the field of immunology and infectious diseases.
